How has been the historical performance of Star Imaging?

Star Imaging has shown significant growth in shareholder's funds and total assets over the past four years, with shareholder's funds increasing to 47.15 Cr and total assets to 98.16 Cr by March 2025. Profit before tax improved to 21.00 Cr, although cash flow from operating activities turned negative, indicating potential cash generation challenges.

Answer:<BR>The historical performance of Star Imaging shows a significant increase in shareholder's funds and total assets over the past four years, with no standalone results declared. As of March 2025, shareholder's funds reached 47.15 Cr, up from 31.35 Cr in March 2024, and total assets also increased to 98.16 Cr from 81.64 Cr in the previous year. The company has seen a rise in total reserves, which grew to 33.65 Cr in March 2025 from 29.85 Cr in March 2024. Long-term borrowings decreased slightly to 14.87 Cr in March 2025 from 15.71 Cr in March 2024, while short-term borrowings increased to 17.86 Cr from 14.93 Cr in the same period. The profit before tax improved to 21.00 Cr in March 2025, compared to 16.00 Cr in March 2024, indicating a positive trend in profitability.<BR><BR>Breakdown:<BR>Star Imaging's financial metrics reflect a positive trajectory in its consolidated balance sheet and cash flow results. The company's shareholder's funds have shown a robust increase, rising from 18.36 Cr in March 2022 to 47.15 Cr in March 2025, while total assets have also grown significantly from 58.34 Cr to 98.16 Cr over the same period. Total reserves increased notably, indicating a strengthening financial position. Despite a slight decrease in long-term borrowings, short-term borrowings have risen, suggesting a shift in financing strategy. Profit before tax has improved markedly, moving from 0.00 Cr in March 2023 to 21.00 Cr in March 2025, showcasing enhanced operational performance. However, cash flow from operating activities turned negative in March 2025, indicating challenges in cash generation despite the overall growth in profitability.

Which are the latest news on Star Imaging?

Why is Star Imaging falling/rising?

As of 03-Dec, Star Imaging and Path Lab Ltd's stock price is Rs 126.00, reflecting a 4.55% decrease. The stock has been on a downward trend, underperforming the market and trading below key moving averages, despite increased investor participation.

As of 03-Dec, Star Imaging and Path Lab Ltd's stock price is falling, currently at Rs 126.00, which reflects a decrease of Rs 6.0 or 4.55%. The stock has been on a downward trend, having lost 6.67% over the past week and 14.81% over the past month, significantly underperforming the Sensex, which gained 1.34% in the same period. <BR><BR>Today, the stock has underperformed its sector by 3.65% and has experienced a consecutive decline for the last four days, resulting in a total drop of 6.77% during this timeframe. The stock also touched an intraday low of Rs 124.05, indicating a significant loss of value. Furthermore, it is trading below all key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), which typically signals a bearish trend.<BR><BR>Despite these negative indicators, there has been a notable increase in investor participation, with delivery volume rising by 76.47% compared to the 5-day average. However, this increase in trading volume has not translated into a price recovery, as the stock remains close to its 52-week low, just 2.38% above Rs 123. Overall, the combination of consistent declines, poor performance relative to the market, and trading below moving averages contributes to the current downward movement of Star Imaging's stock price.

Is Star Imaging overvalued or undervalued?

As of December 3, 2025, Star Imaging is considered overvalued with a valuation grade of expensive, a PE ratio of 13.80, and strong returns on capital, despite a recent stock price decline and better valuations compared to peers like Max Healthcare and Apollo Hospitals.

As of 3 December 2025, Star Imaging's valuation grade has moved from very expensive to expensive, indicating a slight improvement in its perceived value. The company is currently considered overvalued. Key ratios include a PE ratio of 13.80, an EV to EBITDA of 8.67, and a ROE of 33.81%. In comparison to peers, Max Healthcare has a significantly higher PE ratio of 74.7, while Apollo Hospitals is at 61.84, highlighting that Star Imaging's valuation is more reasonable yet still on the higher side.<BR><BR>Despite the recent decline in stock price, with a 1-month return of -14.81% compared to a Sensex return of 1.34%, the company's strong ROCE of 31.55% and a PEG ratio of 0.00 suggest that it is generating substantial returns on capital. However, given the overall market conditions and peer comparisons, Star Imaging remains overvalued in its current state.